Skip navigation

Renasight

Kidney gene panel

 

Renasight is a test to determine if there is a genetic cause for an individual’s kidney disease or if there is an increased hereditary risk due to family history. The test uses a blood or saliva sample to test 385 genes associated with chronic kidney disease (CKD). Results are available in approximately 3 weeks.

See more. Know more. With Renasight.

  • Leverages next-generation sequencing and other methodologies on more than 380 genes associated with kidney disease
  • Identifies autosomal dominant, autosomal recessive, and X-linked disorders
  • Reports out pathogenic and likely pathogenic variants that were selected by genetic experts to provide actionable information
  • > 99% detection rates across the genes screened1

 

Download gene list

OH_REN_Clinician_s1
OH_REN_Clinician_s2.1

Built on evidence

A recent New England Journal of Medicine publication assessing the incidence of genetic disease in kidney disease population found ~1 in 10 patients have a genetic diagnosis.2

Pinpoint and plan

Testing at the molecular level offers deeper insights to help deliver individualized patient care. In 89% of patients with kidney disease, a genetic diagnosis had implications for clinical management.2

OH_REN_Clinician_s2.2

Integrate Renasight for better patient care

OH_REN_Clinician_s3.1

Gain prognostic insight

OH_REN_Clinician_s3.2

Identify an etiology for patients with unknown cause of their kidney disease

OH_REN_Clinician_s3.3

Prescribe targeted therapies

OH_REN_Clinician_s3.4

Refer patients for extra-renal features

OH_REN_Clinician_s3.5

Test family members and offer genetic counseling

OH_REN_Clinician_s3.6

Enroll patients in clinical trials

Learn more about Renasight: Clinician brochure

Commitment to affordability

We welcome all insurance plans and provide affordable testing through a variety of payment methods. Natera offers discounted self-pay pricing and financial assistance through our compassionate care program.

The Natera team is here to help you with any billing or reimbursement questions at +1 650.425.4005.

Commitment to affordability

Request more information about Renasight



References

1Natera data on file

2Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.